Evidence map›Paper›PMID 33800271›Full record

ReviewCells2021

Mural Cells: Potential Therapeutic Targets to Bridge Cardiovascular Disease and Neurodegeneration.

Alexander Lin, Niridu Jude Peiris, Harkirat Dhaliwal, Maria Hakim, Weizhen Li, Subramaniam Ganesh, Yogambha Ramaswamy, Sanjay Patel, Ashish Misra

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Alexander LinHeart Research Institute, Sydney, NSW 2042, Australia.
Niridu Jude PeirisHeart Research Institute, Sydney, NSW 2042, Australia.
Harkirat DhaliwalHeart Research Institute, Sydney, NSW 2042, Australia.
Maria HakimHeart Research Institute, Sydney, NSW 2042, Australia.
Weizhen LiHeart Research Institute, Sydney, NSW 2042, Australia.
Subramaniam GaneshDepartment of Biological Sciences and Bioengineering, Indian Institute of Technology Kanpur, Kanpur, Uttar Pradesh 208016, India.
Yogambha RamaswamySchool of Biomedical Engineering, Faculty of Engineering, The University of Sydney, Sydney, NSW 2006, Australia.
Sanjay PatelHeart Research Institute, Sydney, NSW 2042, Australia.
Ashish MisraHeart Research Institute, Sydney, NSW 2042, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mural cells collectively refer to the smooth muscle cells and pericytes of the vasculature. This heterogenous population of cells play a crucial role in the regulation of blood pressure, distribution, and the structural integrity of the vascular wall. As such, dysfunction of mural cells can lead to the pathogenesis and progression of a number of diseases pertaining to the vascular system. Cardiovascular diseases, particularly atherosclerosis, are perhaps the most well-described mural cell-centric case. For instance, atherosclerotic plaques are most often described as being composed of a proliferative smooth muscle cap accompanied by a necrotic core. More recently, the role of dysfunctional mural cells in neurodegenerative diseases, such as Alzheimer's and Parkinson's disease, is being recognized. In this review, we begin with an exploration of the mechanisms underlying atherosclerosis and neurodegenerative diseases, such as mural cell plasticity. Next, we highlight a selection of signaling pathways (PDGF, Notch and inflammatory signaling) that are conserved across both diseases. We propose that conserved mural cell signaling mechanisms can be exploited for the identification or development of dual-pronged therapeutics that impart both cardio- and neuroprotective qualities.

Indexed as

Alzheimer DiseaseAnimalsAtherosclerosisCardiotonic AgentsDisease Models, AnimalGene Expression RegulationHumansMiceMuscle, Smooth, VascularMyocytes, Smooth MuscleNeuroprotective AgentsParkinson DiseasePericytesPlaque, AtheroscleroticPlatelet-Derived Growth FactorReceptors, NotchCardiotonic AgentsNeuroprotective AgentsPlatelet-Derived Growth FactorReceptors, NotchAlzheimer’s diseaseatherosclerosiscardiovascular diseasemural cellsneurodegenerationpericytesvascular smooth muscle cells

Identifiers

PMID33800271
PMCPMC7999039

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.